Jasper Therapeutics Unveils Promising Preclinical Data on Briquilimab at AAAAI Annual Meeting
REDWOOD CITY, Calif. Feb. 23, 2024 - Jasper Therapeutics, a leading biotechnology company specializing in the development of briquilimab, an innovative antibody therapy for mast cell driven diseases like chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), presented groundbreaking findings from three preclinical studies at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, D.C. held from February 23-26.
Briquilimab has shown great potential in targeting the c-Kit (CD117) protein implicated in the development of mast cell-driven diseases, which are characterized by the release of histamines leading to allergic symptoms such as hives, itching, and swelling. By specifically targeting mast cells, briquilimab aims to offer a more effective and targeted treatment option for these debilitating conditions.
The highlight of the conference was an oral presentation on one of the studies conducted by Jasper Therapeutics. The study demonstrated the notable efficacy of briquilimab in reducing mast cell activation and allergic responses in an animal model of chronic spontaneous urticaria. Animals treated with briquilimab experienced a significant reduction in symptom severity, including a decrease in hives, itching, and swelling compared to the control group.
In addition to the oral presentation, Jasper Therapeutics also showcased two poster presentations featuring their other preclinical studies. The first poster highlighted the therapeutic potential of briquilimab in chronic inducible urticaria, showcasing its ability to suppress mast cell degranulation and alleviate symptoms triggered by environmental stimuli like temperature changes, exercise, and pressure. The second poster focused on the safety and tolerability profile of the antibody therapy, emphasizing its excellent safety profile with no significant adverse events observed during the studies.
These promising results indicate that briquilimab has the potential to revolutionize the treatment landscape for mast cell-driven diseases like chronic spontaneous urticaria and chronic inducible urticaria. Mast cell-driven diseases are often challenging to manage and can significantly impact patients’ quality of life. The availability of an antibody therapy specifically targeting c-Kit could provide much-needed relief and improve outcomes for millions of individuals suffering from these conditions.
Dr. Sarah Thompson, Chief Medical Officer at Jasper Therapeutics, expressed excitement about the results and the potential impact of briquilimab on patient care. We are delighted to share these encouraging findings from our preclinical studies at the AAAAI Annual Meeting. This data reveals the immense potential of briquilimab as a targeted therapy for mast cell-driven diseases. Our team is thrilled with the results and remains committed to advancing briquilimab through clinical development to ultimately benefit patients.
In summary, Jasper Therapeutics’ presentation at the AAAAI Annual Meeting has highlighted the promising preclinical data on briquilimab, a novel antibody therapy targeting mast cell-driven diseases. With its ability to suppress mast cell activation and allergic responses, briquilimab holds immense potential in revolutionizing the treatment approach for chronic spontaneous urticaria and chronic inducible urticaria. As further clinical studies are initiated, the outlook for this therapy looks incredibly promising, offering hope for patients suffering from these debilitating conditions.
Comments